Abstract Body

Background

The World Health Organization endorses 3 months of weekly isoniazid and rifapentine (3HP) as TB preventive therapy (TPT) in people with HIV (PWH) on once-daily dolutegravir (DTG)-based antiretroviral treatment (ART). Optimal dosing of DTG to maintain HIV viral suppression in pregnancy while taking 3HP or 1 month of daily isoniazid and rifapentine (1HP) has not been studied.

Methods

DOLPHIN-Moms (NCT95122026) is an open-label phase II trial in South Africa investigating the safety and pharmacokinetics of DTG in pregnant PWH initiated on 1HP or 3HP. Pregnant PWH at 20-34 weeks’ gestation with HIV viral suppression on DTG-based ART were randomized 1:1 to receive 1HP or 3HP. All initiated twice-daily DTG prior to starting 1HP or 3HP on day 1. Twenty-five participants in each arm had sparse DTG PK sampling on days 1 (pre-HP) and 17 (11h and 12h post DTG dose). DTG dosing was considered acceptable if 5th percentile DTG troughs were >158 ng/mL. HIV viral load was measured at screening, delivery, and TPT completion (1HP: week 4, 3HP: week 12). We estimated population PK of DTG using non-linear mixed effects modeling and performed Monte Carlo simulations of daily DTG dosing with 1HP and 3HP.

Results

Among 50 pregnant PWH, at entry, the median age was 33 years (IQR 31–37), gestational age 26.8 weeks (IQR 23–30), and CD4 696 cells/mm3 (IQR 459–864). All had HIV viral suppression. On day 1, there were no significant differences in median DTG troughs between 1HP and 3HP (2730 vs 2890 ng/mL, p=0.91). On day 17, median (5th-95th percentile) troughs were 871 ng/mL (391–1754) in the 1HP arm and 1890 ng/mL (843–4764) with 3HP (p<0.01). At day 17, one participant per arm had DTG troughs <64ng/mL (Fig 1A): both had documented nonadherence and received counseling; one had detectable viral load at delivery (6697 copies/mL) and viral suppression at 12 weeks postpartum (3HP arm); the other remained virally suppressed throughout. Excluding these two participants, simulations of once-daily DTG predicted median (5th–95th percentile) DTG troughs of 88ng/mL (28–212) with 1HP and 436ng/mL (209–781) with 3HP.

Conclusions

In pregnant PWH, 1HP and 3HP administered with twice-daily DTG yields therapeutic DTG troughs and viral suppression among participants with adherence. Simulations predict once-daily dosing will achieve target DTG concentrations with 3HP but not 1HP. The next phase of the trial (confirming PK and virologic outcomes of once-daily DTG with 3HP in pregnant PWH) is ongoing.